A Phase II Trial Assessing Immunogenicity and Safety of COVID-19 mRNA Vaccine BNT162b2 in Adult Volunteers With no History of SARS-CoV-2 Infection Administered With Two Doses of Vaccine (D1-D29) and in Adult Volunteers With Documented History of SARS-CoV-2 Infection (of More Than 5 Months) Administered With Only One Dose of Vaccine
Latest Information Update: 28 Dec 2023
At a glance
- Drugs Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Acronyms CoviCompareP
- 13 Dec 2023 Status changed from active, no longer recruiting to completed.
- 16 Aug 2022 Planned End Date changed from 30 Oct 2023 to 30 Nov 2023.
- 02 Aug 2021 Planned End Date changed from 8 Dec 2023 to 30 Oct 2023.